In an important ruling in the case of Glaxo SmithKline Consumer Healthcare (“GSK India”), the Chandigarh Bench of the Income Tax Appellate Tribunal (‘Tribunal’) has laid out important principles in relation to transfer pricing adjustments on marketing intangibles following the guidelines laid down by the SB in the case of LG India. This attached alert by BMR analyses the ruling and principles laid down.
Disclaimer: The information/opinions expressed in this report/newsletter are those of the author. This website has not verified the accuracy of the claims made in the report/newsletter, nor does it agree or disagree with or endorse any information/opinions contained in this report/newsletter.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
